Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: SDZXF )

41.30 UNCHANGED
Streaming Delayed Price Updated: 10:52 AM EDT, Mar 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 41.30
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 41.30
Today's Range 41.30 - 41.30
52wk Range 27.31 - 49.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
Via Benzinga

Performance

YTD
+0.84%
+0.84%
1 Month
-14.59%
-14.59%
3 Month
-3.40%
-3.40%
6 Month
+1.02%
+1.02%
1 Year
+32.57%
+32.57%

More News

Read More
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Via Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Via Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.